---
title: "The Chinese team showcases new achievements in interventional treatment for heart disease in the United States"
description: "A Chinese research team presented a new medical device for treating aortic regurgitation and its latest clinical data at the Global Transcatheter Cardiovascular Therapeutics Annual Meeting in San Fran"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262742438.md"
published_at: "2025-10-26T03:08:03.000Z"
---

# The Chinese team showcases new achievements in interventional treatment for heart disease in the United States

> A Chinese research team presented a new medical device for treating aortic regurgitation and its latest clinical data at the Global Transcatheter Cardiovascular Therapeutics Annual Meeting in San Francisco, USA. The device, named "J-VALVE TF Transcatheter Aortic Valve System," achieves shorter surgery times and faster patient recovery through minimally invasive surgery, showcasing China's innovation and effectiveness in the medical device field

The Global Interventional Cardiovascular Therapy Conference 2025 opened on the 25th in San Francisco, California, USA. A Chinese research team presented the latest clinical data on medical devices for treating aortic regurgitation at the conference, showcasing the innovation, effectiveness, and safety of Chinese original devices. Academician of the Chinese Academy of Sciences and Professor Wang Jian'an from the Second Affiliated Hospital of Zhejiang University School of Medicine introduced the two-year clinical follow-up data of the "J-VALVE TF Transcatheter Aortic Valve System" for treating aortic regurgitation. This valve is accessed via a vascular approach, achieving a more minimally invasive treatment for aortic regurgitation through the synergistic innovation of device design and surgical techniques, resulting in shorter operation times and faster patient recovery

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 美股的 “危险信号” | 本月标普 500 指数成分股在八个交易日内下跌 7% 或以上的股票数量已经超过 100 只，直逼 2022 年美股熊市的水平。 虽然这不像新冠疫情或关税危机期间那样极端，但该指标超过 100 通常意味着更大范围的下滑，而这种情况目前还没有发 | [Link](https://longbridge.com/en/news/276185288.md) |
| 一文读懂 2026 年至今的全球市场：什么在涨？美股为何不行？这种趋势会持续吗？ | 高盛报告揭示 2026 年市场新风向：周期性资产上涨仍有空间；但 AI 等热门主题估值过高，高波动或成为未来常态；美元将持续疲软；建议警惕高估值板块，分散股票持仓、保持健康的非美敞口（包括新兴市场），以及较长期限指数波动率的做多头寸。 | [Link](https://longbridge.com/en/news/276406606.md) |
| 特朗普暗示违法征收的关税不退了，美财长称今年关税收入将 “基本保持不变” | 美国总统特朗普暗示不会退还被最高法院裁定违法的关税，预计 2026 年关税收入将保持不变。特朗普计划签署行政令，对全球商品加征 10% 进口关税，取代被推翻的关税。财长贝森特表示，政府将利用替代法律权力维持关税收入，强调国家安全和财政收入不 | [Link](https://longbridge.com/en/news/276494362.md) |
| IRhythm｜10-K：2025 财年营收 7.47 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276388892.md) |
| Guardant Health｜10-K：2025 财年营收 9.82 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276387081.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
